海尔生物收盘下跌1.85%，滚动市盈率32.80倍，总市值111.28亿元

Company Overview - Qingdao Haier Biomedical Co., Ltd. focuses on providing optimal user experiences for life science users, including pharmaceutical and biological enterprises, research institutions, hospitals, and public health organizations [2] - The company has developed two main business segments: life sciences and medical innovation, offering comprehensive digital solutions such as smart laboratories and digital hospitals [2] Product Portfolio - Major products include low-temperature storage boxes, automated biological sample storage systems, fully automated cell culture workstations, and various medical automation products [2] - The company has received multiple awards and certifications, enhancing its innovation capabilities in life sciences and medical fields [2] Financial Performance - For Q1 2025, the company reported revenue of 689 million yuan, a year-on-year increase of 0.30%, and a net profit of 110 million yuan, a decrease of 19.88% [3] - The gross profit margin stands at 48.35% [3] Market Position - As of August 19, the company's stock closed at 35.0 yuan, with a rolling PE ratio of 32.80 times, and a total market capitalization of 11.128 billion yuan [1] - The average PE ratio in the medical device industry is 59.49 times, with a median of 40.19 times, placing the company at the 64th position in the industry ranking [1][3] Institutional Holdings - As of Q1 2025, there is one institutional holder of the company, with a total holding of 430,200 shares valued at 1.3 million yuan [1]